	US 12,303,577 B2
	Photonic barrier for topical use, comprising bismuth oxide colloids
Han Athalin, Nantes (FR); and Jean-Noël Thorel, Paris (FR)
Assigned to BIONUCLEI, Aix en Provence (FR)
Appl. No. 17/279,365
Filed by BIONUCLEI, Aix en Provence (FR)
PCT Filed Oct. 1, 2019, PCT No. PCT/FR2019/052321 § 371(c)(1), (2) Date Mar. 24, 2021, PCT Pub. No. WO2020/070437, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 1859066 (FR), filed on Oct. 1, 2018.
Prior Publication US 2021/0401686 A1, Dec. 30, 2021
Int. Cl. A61K 8/02 (2006.01); A61K 8/19 (2006.01); A61K 8/81 (2006.01); A61Q 17/04 (2006.01); A61Q 19/08 (2006.01); B82Y 5/00 (2011.01)

CPC A61K 8/19 (2013.01) [A61K 8/8176 (2013.01); A61Q 17/04 (2013.01); A61K 2800/413 (2013.01); B82Y 5/00 (2013.01)]

20 Claims

1. A topical composition creating a photonic barrier against electromagnetic radiation ranging from ultraviolet radiation to visible radiation comprising bismuth oxide colloids Bi₂O₃in monoclinic form of alpha phase having a crystal lattice, wherein the bismuth oxide colloids are doped with iron, wherein the iron represents 0.01 to 0.15% by mass relative to the mass of Bi₂O₃, and is present in the crystal lattice, and wherein the iron-doped bismuth oxide colloids have reduced photocatalytic activity as compared to corresponding bismuth oxide colloids that have not been doped with iron.